GHRP-2 Dosage: What Community Protocols Report
Last updated May 19, 2026 · Reviewed by Grey Peptides Editorial Board · ✓ Primary-sourced
← GHRP-2 encyclopedia entry · See also: GHRP-6 dosage · Ipamorelin dosage
GHRP-2 (pralmorelin) is approved in Japan as a diagnostic agent for growth-hormone secretion testing — but it is not FDA-approved for therapeutic use, and the community use as a GH-boosting peptide is investigational. The figures below reflect community practice, documented for education, not instructions for use.
Educational information, not medical advice. The doses on this page come from approved labels, published studies and, where no study exists, amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
The short version
GHRP-2 is a growth-hormone-releasing peptide — a ghrelin-receptor agonist that triggers a GH pulse. It sits in the same family as ipamorelin and GHRP-6, and its only formal approval anywhere is as a diagnostic (pralmorelin, in Japan) used to test the pituitary's ability to release growth hormone. That diagnostic approval is sometimes misread as a therapeutic green light; it is not.
What community protocols report
Community-reported. Amounts users report, recorded for education. Not a recommendation, and not a dose any study has shown to be safe or effective.
| Parameter | Commonly reported |
|---|---|
| Amount | ~100–300 mcg per dose |
| Frequency | 1–3× daily |
| Timing | Pre-bed and/or post-workout |
| Route | Subcutaneous |
As with the other GH secretagogues, the timing tracks the body's own GH rhythm, and GHRP-2 is frequently combined with a GHRH analog like CJC-1295 on the complementary-mechanism theory. These conventions come from community use, not approval-grade therapeutic trials.
GHRP-2 is more potent at releasing GH than ipamorelin, but it also raises cortisol, prolactin, and appetite more. Ipamorelin is the "clean," selective option with little of that off-target effect. GHRP-6 is the strongest appetite stimulant of the three. The trade-off is potency versus selectivity — which is the main reason people choose one over another. See the ipamorelin and GHRP-6 dosage pages.
Reconstitution basics
GHRP-2 is supplied as a lyophilized powder requiring reconstitution with bacteriostatic water before microgram doses can be measured. The Reconstitution Calculator converts vial strength and diluent volume into an exact draw; it cannot verify the contents of an unregulated vial.
Frequently asked questions
Does the Japanese diagnostic approval make it safe to use as a therapy?
No. A diagnostic approval covers a single, controlled test dose for assessment — it is not the same as approval for repeated therapeutic use, and it does not apply in the US.
Why combine it with CJC-1295?
The GHRH analog raises the baseline GH drive while GHRP-2 triggers a pulse; the pairing is a community convention, not a validated combination.
Will it stimulate appetite?
Yes, more than ipamorelin — appetite stimulation is one of the off-target effects that distinguishes the older GHRPs from the selective ones.
Sources
- Bowers CY. Growth hormone-releasing peptides — pharmacology and the GHRP class.
- Pralmorelin (GHRP-2) diagnostic approval, Japan (growth-hormone stimulation testing).
Medical disclaimer: Education only, not medical advice. GHRP-2 is not FDA approved for therapeutic use. Dosing figures reflect community practice, not a recommendation. Do not self-administer; consult a licensed clinician.